Steven Nissen, MD
Cardiovascular Disease · Cleveland, OHNPI 1871685487
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $133,560 of the $149,125 with a category attached, or 89.6%. Eli Lilly accounts for 74.4% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2024 at $72,452 and has fallen 97.3% since, to $1,959 in 2025. Among cardiovascular disease clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 290 payments — averaging $514.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$111K
- Novartis Pharma AG$21K
- Novartis$10K
- AstraZeneca$3K
- Amgen$2K
- Glenmark Pharmaceuticals Limited$2K
- plus $847 from 4 others
Across 22 payments — averaging $235,830 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$3.8M
- AstraZeneca$1.4M
- AbbVie$796
- Amgen$38
What the payments were for
- Consulting fees$7,3855%
- Speaking & faculty fees$1,7501%
- Travel & lodging$133,56090%
- Food & beverage$6,0244%
- Education$4050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 225 | $110,879 |
| Novartis Pharma AG | 15 | $20,987 |
| Novartis | 22 | $10,277 |
| AstraZeneca | 15 | $2,589 |
| Amgen | 4 | $1,796 |
| Glenmark Pharmaceuticals Limited | 1 | $1,750 |
| Lilly USA, LLC | 2 | $459 |
| Astrazeneca UK Limited | 4 | $205 |
| Genentech, Inc. | 1 | $145 |
| Halozyme Inc | 1 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LCZ696_ENTRESTO_CARDIOVASCULAR$11,004
- ACZ885M_ILARIS_IMMUNOLOGY$11,004
- RLX030A_INVESTIGATIONAL_CARDIOVASCULAR$11,004
- LIK066X_INVESTIGATIONAL_CARDIOVASCULAR$11,004
- ENTRESTO$9,638
- Repatha$1,785
- LEQVIO$249
- LCZ696D_ENTRESTO_CARDIOVASCULAR$213
- MOUNJARO$185
- EPANOVA$118
How this compares
$149,125 in reported general payments places this provider in the 95th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ezetimibe | 30 | $1,158 |
| Rosuvastatin Calcium | 56 | $910 |
| Telmisartan | 14 | $605 |
| Atorvastatin Calcium | 16 | $167 |
| Amlodipine Besylate | 14 | $138 |
| Lisinopril | 13 | $48 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Cleveland
- Guilherme AttizzaniCleveland$1.3M
- Abraham LincoffCleveland$369K
- Oussama WazniCleveland$367K
- Ian NeelandCleveland$329K
- Mazen HannaCleveland$208K
- Brian HoitCleveland$207K
- Daniel CantillonCleveland$140K
- Serge HarbCleveland$134K
- Wael JaberCleveland$124K
- Milind DesaiCleveland$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.